Literature DB >> 7467363

[Efficacy of Vaccination Against Tick-Borne Encephalitis].

C Kunz, H Hofmann, F X Heinz, H Dippe.   

Abstract

Since 1973 blood samples have been investigated at random for the presence of antibodies to tick-borne encephalitis (TBE) virus in persons vaccinated with the Austrian TBE vaccine. The immunization schedule was to doses given 1 to 3 months apart and a third dose injected 9 to 12 months later. This resulted in a seroconversion rate of 96% (n=444) in the haemagglutination-inhibition (HI) test and of 99% in the ELISA. The vaccine also induced high titres of complement-fixing anti-bodies. Antibody formation did not depend significantly on the age of the vaccinees. After three years, 66% (n=321) of those vaccinated still possessed antibodies in the HI test and 87% in the ELISA. Moreover, antibodies were still found in the sera of some persons at the end of the observation period (i.e. 6 years). Persons who had become seronegative still responded positively to a booster dose of vaccine. In a large number of persons it was evident that the intervals between injection of the single doses of vaccine can be extended considerably without jeopardizing the success of vaccination. The protection rate is larger than 99%.

Entities:  

Mesh:

Year:  1980        PMID: 7467363

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  4 in total

1.  Detectability of IgM antibodies against TBE virus after natural infection and after vaccination.

Authors:  H Hofmann; C Kunz; F X Heinz; H Dippe
Journal:  Infection       Date:  1983 May-Jun       Impact factor: 3.553

2.  Tick-borne encephalitis in a 3-month-old child.

Authors:  H M Grubbauer; H J Dornbusch; D Spork; G Zobel; M Trop; W Zenz
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

3.  Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report.

Authors:  R J Phillpotts; J R Stephenson; J S Porterfield
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

4.  An antivector vaccine protects against a lethal vector-borne pathogen.

Authors:  Milan Labuda; Adama R Trimnell; Martina Licková; Mária Kazimírová; Gillian M Davies; Olga Lissina; Rosie S Hails; Patricia A Nuttall
Journal:  PLoS Pathog       Date:  2006-04-07       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.